HB-EGF, which is a ligand that binds to both EGFR and HER4, is abundantly expressed in EGFR-mutated NSCLC cells, whereas the HB-EGF inhibitor suppresses tumorigenesis [81]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.